A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: Implication for immunotherapy of human hepatocellular carcinoma

Hepatology

Volumn 28, Issue 1, 1998, Pages 57-67

  Atarashi, Yoshinari ^a   Yasumura, Satoshi ^a   Nambu, Shuji ^a   Yoshio, Yukimatsu ^a   Murakami, Jun ^a   Takahara, Terumi ^a   Higuchi, Kiyohiro ^a   Watanabe, Akiharu ^a   Miyata, Keizo ^b   Kato, Masanari ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b ISHIHARA SANGYO KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

F 4614; MUTANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA MUTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL CYCLE; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17144440090     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280110     Document Type: Article

References (19)

1. Takayasu K, Moriyama N, Muramatu Y, Makuuchi M, Hasegawa H, Okazaki N, Hirohashi S. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. AJR 1990;155:49-54.
2. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teretani T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. HEPATOLOGY 1995;22:1027-1033.
3. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. HEPATOLOGY 1995;21:650-655.
4. Franco D, Capussotti L, Smadja C, Bouzari H, Meakins J, Kemeny F, Grange D, et al. Resection of hepatocellular carcinomas: results in 72 European patients with cirrhosis. Gastroenterology 1990;98:733-738.
5. Hsu H, Wei T, Tsang Y, Wu M, Lin Y, Chuang S. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 1986;57:1184-1191.
6. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, Hata Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. Cancer 1991;68:1524-1530.
7. Shiina S, Hata Y, Niwa Y, Komatsu Y, Tanaka T, Yoshiura K, Hamada E, et al. Multiple-needle insertion method in percutaneous ethanol injection therapy for liver neoplasm. Gastroenterol Jpn 1991;26:47-50.
8. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. HEPATOLOGY 1993;18:1121-1126.
9. Shiina S, Niwa Y, Omata M. Percutaneous ethanol injection therapy for liver neoplasms. Seminars in Interventional Radiology 1993;10:57-68.
10. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino, Jr. MA, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 1985;230: 943-945.
11. Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furuichi H. Recombinant human tumor necrosis factor-II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunopharmacol 1986;8:357-368.
12. Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, et al. Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res 1987;47: 3707-3711.
13. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-3670.
14. Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 1986;323:86-89.
15. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of the receptors on human T cells and TNF-α-mediated enhancement of T cell response. J Immunol 1987;138:1786-1790.
16. Robertson MJ, Manley TJ, Donahue C, Levine H, Ritz J. Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol 1993;150:1705-1714.
17. Ranges GE, Figari IS, Espevik T, Palladino Jr. MA. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis α. J Exp Med 1987;166:991-998.
18. Pfizenmaier K, Scheurich P, Schluter C, Kronke M. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol 1987;138:975-980.
19. Taguchi T, Sohmura Y. Clinical studies with TNE Biotherapy 1991;3: 177-186.